Monitoring Inflammation And Neurodegeneration In Multiple Sclerosis With Simoa
date11 September 2020
In this presentation, developed for MSVirtual2020 (ACTRIMS-ECTRIMS Joint Virtual Meeting), Dr. Sharel Figueredo explains how Simoa enables precise measurements of protein biomarkers in blood and CSF, even when biomarker concentration is low. She also shares data from clinical trials in which Simoa was used to help accurately reflect inflammation and neuroaxonal injury.
By enabling the detection of key neurodegenerative and inflammatory biomarkers with the greatest possible sensitivity, Simoa offers the tools that now allow researchers to see a more complete picture of MS, from early stages to treatment response.
Share this page